Preclinical Trials Demonstrate the Efficacy of Nanoparticle-Based Vaccine
Written by AZoNanoMay 25 2021
Preclinical studies have demonstrated the effectiveness of an experimental flu vaccine that contains scores of microscopic spherical sacs carrying infection-fighting proteins all through the body.
The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Image Credit: University at Buffalo.
As explained in a study recently published in the
Proceedings of the National Academy of Sciences on May 24
th, 2021, the experimental flu vaccine can:
Enhance the effectiveness of seasonal flu vaccines, which generally work 40% to 60% of the time, as per the U.S. Centers for Disease Control and Prevention
Nanoparticle based shot could boost efficacy, accelerate production of seasonal flu vaccines Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that inefficiency.
Key to the vaccine s success is a liposome the developers created called cobalt-porphyrin-phospholipid, or CoPoP. They are tiny spherical sacs, which are small enough to be considered nanoparticles, and they form the backbone of the vaccine platform.
Described in a study published on May 24 by the Proceedings of the National Academy of Science, the experimental vaccine has reportedly proven effective in preclinical studies.
Jonathan Lovell, associate professor
Department of Biomedical Engineering
An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body has proven effective in preclinical studies.
Described in a study published May 24 in the Proceedings of the National Academy of Sciences, the vaccine has the potential to:
Improve the effectiveness of seasonal flu vaccines, which typically work 40-60% of the time, according to the U.S. Centers for Disease Control and Prevention.
Take less time to produce large quantities because, unlike most seasonal flu vaccines, it is not created in embryonated chicken eggs.
Use smaller doses, thereby increasing vaccine supplies, which can be critical given the unpredictable nature of influenza.
Through the fourth quarter of 2020, businesses in Greenwood received $28.3 million in health-related relief from the CARES act issued by the Department of Health and Human Services.
According to numbers reported through the fourth quarter of 2020, businesses in South Carolina received $1.2 billion in health-related relief from the CARES act issued by the Department of Health and Human Services. The largest recipient of funding in the state was Prisma Health-Upstate with a total of $131 million. The average loan size in the city was $514,922 while the state s average loan amount was $258,718.
Of the money distributed, $30 billion went out automatically to health providers based on previous year medicare payments. If the money wasn t returned within 90 days the provider is then automatically entered into the repayment terms that are issued by HHS. With the money going out automatically and the rules constantly changing, some of the businesses that received the money weren t eligible
Compañía de seguros estadounidense adquirirá MMM y sus afiliados metro.pr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.pr Daily Mail and Mail on Sunday newspapers.